Asthma is a common lung disease affecting 300 million people worldwide. Allergic asthma is recognized as a prototypical Th2 disorder, orchestrated by an aberrant adaptive CD4+ T helper (Th2/Th17) cell immune response against airborne allergens, that leads to eosinophilic inflammation, reversible bronchoconstriction, and mucus overproduction. Other forms of asthma are controlled by an eosinophil-rich innate ILC2 response driven by epithelial damage, whereas in some patients with more neutrophilia, the disease is driven by Th17 cells. Dendritic cells (DCs) and macrophages are crucial regulators of type 2 immunity in asthma. Numerous lipid mediators including the eicosanoids prostaglandins and leukotrienes influence key functions of these cells, leading to either pro- or anti-inflammatory effects on disease outcome. In this review, we will discuss how eicosanoids affect the functions of DCs and macrophages in the asthmatic lung and how this leads to aberrant T cell differentiation that causes disease.

Additional Metadata
Keywords Asthma, Dendritic cells, Eicosanoids, Leukotrienes, Macrophages, Prostaglandins
Persistent URL dx.doi.org/10.3389/fimmu.2018.02006, hdl.handle.net/1765/110239
Journal Frontiers in Immunology
Citation
Debeuf, N. (Nincy), & Lambrecht, B.N.M. (2018). Eicosanoid control over antigen presenting cells in asthma. Frontiers in Immunology (Vol. 9). doi:10.3389/fimmu.2018.02006